GSK ’s Benlysta shows positive outcome in Phase II continuation trial for SLE

GlaxoSmithKline (GSK) reported positive data from the Phase II ten-year continuation clinical trial of Benlysta (belimumab) in combination with standard-of-care for patients suffering from systemic lupus erythematosus (SLE).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news